Showing papers by "Paula Ghaneh published in 2020"
TL;DR: There was no difference in resection rate between arms, however neoadjuvant therapy had a significant survival benefit compared with immediate surgery, and overall survival and toxicity.
Abstract: 4505Background: Patients with borderline resectable pancreatic cancer have poor survival and low resection rates. Neoadjuvant therapy may improve the outcome for these patients. The aim of this tri...
126 citations
University of Leeds1, Leeds Teaching Hospitals NHS Trust2, Institute of Cancer Research3, The Royal Marsden NHS Foundation Trust4, University College London5, Cambridge University Hospitals NHS Foundation Trust6, Royal Liverpool University Hospital7, University Hospitals Birmingham NHS Foundation Trust8, Beatson West of Scotland Cancer Centre9, Norfolk and Norwich University Hospitals NHS Foundation Trust10, University of Glasgow11, Clatterbridge Cancer Centre NHS Foundation Trust12, University of Liverpool13, University of Oxford14, University of Manchester15
TL;DR: Recommendations are given to strategies that limit hospital visits, including through the use of hypofractionated precision radiotherapy and chemoradiotherapy treatment approaches, and factors that modify the risk–benefit balance for treatment in the resectable through to the metastatic settings.
Abstract: The coronavirus disease 2019 (COVID-19) pandemic epicentre has moved to the USA and Europe, where it is placing unprecedented demands on healthcare resources and staff availability. These service constraints, coupled with concerns relating to an increased incidence and severity of COVID-19 among patients with cancer, should lead to re-consideration of the risk-benefit balance for standard treatment pathways. This is of particular importance to pancreatic cancer, given that standard diagnostic modalities such as endoscopy may be restricted, and that disease biology precludes significant delays in treatment. In light of this, we sought consensus from UK clinicians with an interest in pancreatic cancer for management approaches that would minimise patient risk and accommodate for healthcare service restrictions. The outcomes are described here and include recommendations for treatment prioritisation, strategies to bridge to later surgical resection in resectable disease and factors that modify the risk-benefit balance for treatment in the resectable through to the metastatic settings. Priority is given to strategies that limit hospital visits, including through the use of hypofractionated precision radiotherapy and chemoradiotherapy treatment approaches.
19 citations
TL;DR: 18 FDG PET/CT is a useful tool in the preoperative evaluation of patients with pancreatic cancer and tumour TLG offer an independent prognostic value in both potentially operable and metastatic disease settings.
Abstract: Purpose To investigate the value of 18 FDG PET/CT volumetric parameters in the prediction of overall survival (OS) in patients with pancreatic cancer and also, assess their independence relative to well-established clinico-pathological variables. Methods We conducted a retrospective analysis of patients with a confirmed diagnosis of pancreatic cancer who underwent 18 FDG PET/CT. The tumour maximum standardised uptake value (SUVmax) in addition to SUVmean, metabolic tumour volume (MTV) and total lesion glycolysis (TLG) were calculated. The prognostic value of 18 FDG PET/CT and clinico-pathological parameters for OS were assessed using univariate and multivariable analyses. Results A sum of 89 patients were analysed in this study. Median survival for patients categorised as having high TLG (≥55) and low TLG ( Conclusions 18 FDG PET/CT is a useful tool in the preoperative evaluation of patients with pancreatic cancer. Tumour TLG offer an independent prognostic value in both potentially operable and metastatic disease settings.
4 citations
4 citations
TL;DR: Pancreatic anastomosis failure following pancreatic head excision, for suspected pancreatic cancer, leads to longer recovery and failure to start or complete adjuvant chemotherapy.
Abstract: 4619Background: Pancreatic anastomosis failure following pancreatic head excision, for suspected pancreatic cancer, leads to longer recovery and failure to start or complete adjuvant chemotherapy. ...
4 citations
3 citations
Patent•
[...]
27 Aug 2020
TL;DR: In this article, a diagnostic test for the early detection of pancreatic cancer (i.e. pancreatic ductal adenocarcinoma, 'PDAC') or pancreatitis in a cohort of patients was presented.
Abstract: The present disclosure relates to a diagnostic test for the early detection of pancreatic cancer [i.e. pancreatic ductal adenocarcinoma, 'PDAC'] or pancreatitis in a cohort of patients selected for an increased risk of PDAC which is associated with diabetes mellitus (DM) and including treatment regimens for the treatment of subjects with PDAC and kits used in the method of the invention.